View Post

Cancer patients find clinical trials, hope and help

In Clinical Trials by Barbara Jacoby

By: Diane Mapes From: fredhutch.org #NWMetsConf connects metastatic breast cancer patients with trials, treatments, tools and each other Clinical trials — the treatments of tomorrow, today — took top billing at the fourth annual Northwest Metastatic Breast Cancer Conference held Saturday at the Amazon Meeting Center in Seattle. Scientists from Fred Hutchinson Cancer Research Center shared new treatments; National Cancer …

View Post

FDA restructures, renames office that reviews cancer therapies

In Clinical Trials by Barbara Jacoby

From: healio.com The FDA office that reviews applications for cancer therapies has been renamed and reorganized. The Center for Drug Evaluation and Research’s Office of Oncologic Diseases — formerly known as the Office of Hematology and Oncology Products — now is structured under terms of a modernization plan approved last fall. Richard Pazdur, MD — who served as director of …

View Post

Polynoma Presenting Interim Phase III Data for Its Investigational Melanoma Vaccine, Seviprotimut-L

In Clinical Trials by Barbara Jacoby

From: PR Newswire MAVIS Study Identifies Most Responsive Patient Subpopulations, Supporting the Continued Study of Adjuvant Treatment in Localized Melanoma Patients Polynoma LLC, a U.S. immuno-oncology focused biopharmaceutical company and wholly-owned subsidiary of Hong Kong-listed CK Life Sciences Int’l., (Holdings) Inc., is presenting clinical data from MAVIS (Melanoma Antigen Vaccine Immunotherapy Study), its ongoing Phase III clinical study of seviprotimut-L, …

View Post

Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (GBM) Study with INO-5401 In Combination with PD-1 Inhibitor Libtayo® (cemiplimab)

In Clinical Trials by Barbara Jacoby

Source: Inovio Pharmaceuticals, Inc. 80% of Methylated Patients and 75% of Unmethylated Patients Were Disease Progression-Free at 6 Months Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today positive interim results from Inovio’s Phase 2 study (NCT03491683) of newly diagnosed glioblastoma multiforme (GBM) combining Inovio’s INO-5401, a T cell-activating immunotherapy encoding for three tumor-associated antigens (hTERT, WT1, and PSMA), and INO-9012, an …

View Post

Memorial Medical Performs First Breast Cancer Cryoablation in New Mexico

In Clinical Trials by Barbara Jacoby

Source: Memorial Medical Center The first cryoablation of malignant breast cancer in New Mexico was successfully completed on Friday, October 4, 2019, at Memorial’s HealthPlex. In a joint surgery-radiology procedure by General Surgeon Kamran Kamali, MD, Memorial Chief Radiologist Rob Shoots, MD, and Memorial’s radiology team. This accomplishment not only supports Memorial’s mission of patient-centered care but also exemplifies the …

View Post

Cytotron® Granted ‘Breakthrough Device Designation’ by U.S. FDA for Treatment of Breast, Liver, and Pancreatic Cancers

In Clinical Trials by Barbara Jacoby

Source: Shreis Scalene Sciences From: prnewswire.com The Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) granted Shreis Scalene Sciences (Shreis), in Gaithersburg, MD, ‘Breakthrough Device Designation’ for the CYTOTRON® – a CE marked, whole-body therapeutic medical device. “We are confident that the FDA will continue to interact with Shreis under the premises of …

View Post

AstraZeneca reports promising lung cancer results from Phase III immunotherapy drug trial

In Clinical Trials by Barbara Jacoby

By: Alaric DeArment From: medcitynews.com The company said Imfinzi and chemotherapy, with or without tremelimumab, extended progression-free survival in first-line non-small cell lung cancer versus chemotherapy, setting up Imfinzi as a potential competitor to Merck’s Keytruda. Overall survival data are expected next year A British drugmaker’s program to develop an immunotherapy combination for a type lung cancer that could compete …

View Post

Inivata to Employ Liquid Biopsy Test in EORTC Phase II NSCLC Study of Lorlatinib

In Clinical Trials by Barbara Jacoby

By: Staff Reporter From: genomeweb.com Liquid biopsy firm Inivata said today that it is collaborating with the European Organization for Research and Treatment of Cancer, using its InVisionFirst-Lung test in a Pfizer-funded Phase II trial to test lung cancer patients under treatment with the ALK inhibitor lorlatinib (marketed as Lorbrena). Investigators hope that this will help better define resistance mechanisms …

View Post

Linnaeus Therapeutics Announces First Patient Dosed in Its Phase 1/2 Clinical Trial of LNS8801 in Patients with Advanced Cancer

In Clinical Trials by Barbara Jacoby

Source: Linnaeus Therapeutics, Inc. From: PR Newswire Company Commences First-in-Human Study at Multiple Academic Sites in United States Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that it has dosed the first patient in its phase 1/2 clinical trial of LNS8801 in patients with advanced …

View Post

Delayed surgery linked to progression, worse outcomes in ductal carcinoma in situ

In Clinical Trials by Barbara Jacoby

By: Ward WH, et al. Ann Surg Oncol. 2019 From: healio.com Delays to surgery for ductal carcinoma in situ appeared associated with increased risk for progression to invasive disease and worse survival outcomes, according to findings published in Annals of Surgical Oncology. “Delays in treatment time matter in DCIS, although the outcome decrease due to delays is small. As the …